businesspress24.com - Acasti Announces Stock Ticker Symbol Change to ACST on the TSXV
 

Acasti Announces Stock Ticker Symbol Change to ACST on the TSXV

ID: 1467781

(firmenpresse) - LAVAL, QUEBEC -- (Marketwired) -- 11/03/16 -- Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: APO), today announced that as a result of the recent introduction of four-letter root symbols on the TSX Venture Exchange (TSXV), the company applied and received authorization to change its stock ticker symbol to "ACST" (TSX VENTURE: ACST) on TSXV, effective November 8, 2016.

At market opening on that date, Acasti Pharma''s common shares will start trading under the ticker "ACST", on both TSXV and the NASDAQ Stock Market. This root symbol change does not require any action by current shareholders. There is no change in the company''s name, no change in its CUSIP number and no consolidation of capital.

About Acasti Pharma

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre, for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company''s strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major lipids associated with cardiovascular disease risk. For more information, visit .

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.





The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Acasti''s latest Annual Information Form, which also forms part of Acasti''s latest annual report on Form 20-F, and which is available on SEDAR at , on EDGAR at and on the investor section of Acasti''s website at acastipharma.com (the "AIF"). All forward-looking statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Acasti''s public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors."

Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Acasti Contact:
Jan D''Alvise
Chief Executive Officer
450-686-4555



Media & Investor Contact:
Jessica Dyas
Canale Communications
619-849-5385

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Medgenics Reports Third Quarter 2016 Financial Results
Canadian-based Neopharm Labs Completes Acquisition of Boston-Based Averica Discovery Services
Bereitgestellt von Benutzer: Marketwired
Datum: 03.11.2016 - 07:00 Uhr
Sprache: Deutsch
News-ID 1467781
Anzahl Zeichen: 2094

contact information:
Contact person:
Town:

LAVAL, QUEBEC


Phone:

Kategorie:

Drugs


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 238 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Acasti Announces Stock Ticker Symbol Change to ACST on the TSXV
"
steht unter der journalistisch-redaktionellen Verantwortung von

Acasti Pharma Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Acasti Pharma Inc.



 

Who is online

All members: 10 562
Register today: 1
Register yesterday: 2
Members online: 0
Guests online: 70


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.